Maximal androgen blockade (MAB) for the treatment of prostate cancer
Kirby, R.S.
British Journal of Clinical Practice 50(5): 287
1996
ISSN/ISBN: 0007-0947 PMID: 8794610 Document Number: 459943
Document emailed within 1 workday
Related Documents
Fitzpatrick, J.M. 1996: Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against European Urology 29(Suppl): 37-39Neri, B.; Bartalucci, S.; Pieri, A.; Gemelli, M.T.; Rizzo, M.; Bartoletti, R.; Trippitelli, A.; Paoletti, M.C. 1989: Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effects Anticancer Research 9(1): 13-16
Kagebayashi, Y.; Ozono, S.; Takashima, K.; Yoshikawa, M.; Hayashi, Y.; Kaneko, Y.; Maruyama, Y.; Hirao, Y.; Okajima, E. 1997: Total androgen blockade for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 43(3): 197-201
Dahmani, L.; Wagner, B.; Auzanneau, C.; Irani, J.; Doré, B. 2003: Prevalence of osteoporotic fractures in patients treated by androgen blockade for prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(1): 73-78
Nishihara, C.; Kuratsukuri, K.; Tanaka, T.; Kawashima, H.; Nakatani, T. 2011: Successful combined treatment with maximal androgen blockade (MAB), intra arterial chemotherapy and radiation for advanced prostatic ductal adenocarcinoma : report of two cases Hinyokika Kiyo. Acta Urologica Japonica 57(4): 209-212
Zhang, S.-g.; Wang, Y.-h.; Ding, Y.; Wu, Y. 2005: Long term survival results in advanced prostate cancer treated with combined androgen blockade Zhonghua Nan Ke Xue 11(10): 770
Akaza, H. 2005: Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality? Canadian Journal of Urology 12(Suppl 1): 77-80
Pettaway, C.A. 1999: Racial differences in the androgen/androgen receptor pathway in prostate cancer Journal of the National Medical Association 91(12): 653-660
Izbicka, E.; MacDonald, J.R.; Davidson, K.; Lawrence, R.A.; Gomez, L.; Von Hoff, D.D. 1999: 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells Anticancer Research 19(2a): 1285-1291
Bastos, D.A.; Dzik, C.; Rathkopf, D.; Scher, H.I. 2014: Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer Oncology 28(8): 693-699
Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; Kallioniemi, O.P. 1997: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Research 57(2): 314-319
Amler, L.C.; Agus, D.B.; LeDuc, C.; Sapinoso, M.L.; Fox, W.D.; Kern, S.; Lee, D.; Wang, V.; Leysens, M.; Higgins, B.; Martin, J.; Gerald, W.; Dracopoli, N.; Cordon-Cardo, C.; Scher, H.I.; Hampton, G.M. 2000: Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1 Cancer Research 60(21): 6134-6141
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Guan, X-xiang.; Chen, L-bang. 2006: Current opinions on the treatment of androgen-independent prostate cancer Zhonghua Nan Ke Xue 12(11): 1021-1025
Matzkin, H.; Braf, Z. 1994: Complete androgen blockage in the treatment of metastatic prostate cancer Harefuah 126(5): 260-263
Gao, J.; Isaacs, J.T. 1998: Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells Cancer Research 58(15): 3299-3306
Jarrard, D.F.; Kinoshita, H.; Shi, Y.; Sandefur, C.; Hoff, D.; Meisner, L.F.; Chang, C.; Herman, J.G.; Isaacs, W.B.; Nassif, N. 1998: Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells Cancer Research 58(23): 5310-5314
Labrie, F.; Dupont, A.; Bélanger, A.; Lacourcière, Y.; Monfette, J.E.; Monfette, G. 1986: Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer Annales d'Urologie 20(2): 98-106
Roth, B.J. 1999: Androgen-independent prostate cancer: not so chemorefractory after all Seminars in Oncology 26(6 Suppl 18: 43-50
Beuzeboc, P.; Richaud, P. 2003: Androgen replacement therapy and prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(5 Suppl 2: 1276-1277